Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 2/20 | 0.50 |
| ▸ | CES2 | O00748 | 1/20 | 0.50 |
| ▸ | CYP2E1 | P05181 | 2/20 | 0.45 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.45 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.44 |
| ▸ | UBE2M | P61081 | 1/20 | 0.43 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.43 |
| ▸ | CCR5 | P51681 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CDK1 | P06493 | 1/20 | 0.38 |
| ▸ | CDK4 | P11802 | 1/20 | 0.38 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.38 |
| ▸ | CCND1 | P24385 | 1/20 | 0.38 |
| ▸ | CCND3 | P30281 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL424938 | 0.92 | FAAH (0.52) | FAAHCES2CYP2E1CYP2A6CYP2C9 | |
| SCHEMBL427415 | 0.89 | DRD2 (0.52) | FAAHCES2CYP2E1CYP2A6CYP2C9 | |
| SCHEMBL427509 | 0.88 | FAAH (0.50) | FAAHCES2CYP2E1CYP2A6CYP2C9 | |
| SCHEMBL428099 | 0.87 | DRD2 (0.50) | FAAHCES2CYP2E1CYP2A6CYP2C9 | |
| SCHEMBL428291 | 0.87 | FAAH (0.48) | FAAHCES2CYP2E1CYP2A6CYP2C9 | |
| SCHEMBL14950179 | 0.86 | FAAH (0.50) | FAAHCES2UBE2MDCUN1D1CCR5 | |
| SCHEMBL425070 | 0.86 | FAAH (0.50) | FAAHCES2DRD2DRD4 | |
| SCHEMBL427909 | 0.85 | FAAH (0.49) | FAAHCES2UBE2MDCUN1D1CCR5 | |
| SCHEMBL14938037 | 0.85 | FAAH (0.49) | FAAHCES2UBE2MDCUN1D1CCR5 | |
| SCHEMBL426094 | 0.85 | FAAH (0.66) | FAAHCES2CYP2E1CYP2A6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2606035-B1 | PROCES FOR THE SYNTHESIS OF SUBSTITUTED UREA COMPOUNDS | BIAL - PORTELA & CA S A (PT) | 2017-09-06 | — | — | EP | disclosed |
| EP-2606035-B1 | PROCES FOR THE SYNTHESIS OF SUBSTITUTED UREA COMPOUNDS | BIAL - PORTELA & CA S A (PT) | 2017-09-06 | — | — | EP | disclosed |
| US-9458111-B2 | Process for the synthesis of substituted urea compounds | BIAL—PORTELA & CA, S.A. (PT) | 2016-10-04 | — | — | US | disclosed |
| US-9458111-B2 | Process for the synthesis of substituted urea compounds | BIAL—PORTELA & CA, S.A. (PT) | 2016-10-04 | — | — | US | disclosed |
| US-9458111-B2 | Process for the synthesis of substituted urea compounds | BIAL—PORTELA & CA, S.A. (PT) | 2016-10-04 | — | — | US | disclosed |
| US-9353082-B2 | Pharmaceutical compounds | BIAL—PORTELA & CA, S.A. (PT) | 2016-05-31 | — | — | US | disclosed |
| US-9353082-B2 | Pharmaceutical compounds | BIAL—PORTELA & CA, S.A. (PT) | 2016-05-31 | — | — | US | disclosed |
| US-9353082-B2 | Pharmaceutical compounds | BIAL—PORTELA & CA, S.A. (PT) | 2016-05-31 | — | — | US | disclosed |
| EP-2606035-A1 | PROCES FOR THE SYNTHESIS OF SUBSTITUTED UREA COMPOUNDS | BIAL - Portela & CA., S.A. (PT) | 2013-06-26 | — | — | EP | disclosed |
| US-20130123493-A1 | PROCESS FOR THE SYNTHESIS OF SUBSTITUTED UREA COMPOUNDS | BIAL - PORTELA & CA, S.A. (PT) | 2013-05-16 | — | — | US | disclosed |
| US-20130123493-A1 | PROCESS FOR THE SYNTHESIS OF SUBSTITUTED UREA COMPOUNDS | BIAL - PORTELA & CA, S.A. (PT) | 2013-05-16 | — | — | US | disclosed |
| US-20130123493-A1 | PROCESS FOR THE SYNTHESIS OF SUBSTITUTED UREA COMPOUNDS | BIAL - PORTELA & CA, S.A. (PT) | 2013-05-16 | — | — | US | disclosed |
| US-20120065191-A1 | PHARMACEUTICAL COMPOUNDS | BIAL - PORTELA & Cª, S.A. (PT) | 2012-03-15 | — | — | US | disclosed |
| US-20120065191-A1 | PHARMACEUTICAL COMPOUNDS | BIAL - PORTELA & Cª, S.A. (PT) | 2012-03-15 | — | — | US | disclosed |
| US-20120065191-A1 | PHARMACEUTICAL COMPOUNDS | BIAL - PORTELA & Cª, S.A. (PT) | 2012-03-15 | — | — | US | disclosed |
| WO-2012015324-A1 | PROCESS FOR THE SYNTHESIS OF SUBSTITUTED UREA COMPOUNDS | BIAL - PORTELA & CA, S.A. (PT) | 2012-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123493-A1 | PROCESS FOR THE SYNTHESIS OF SUBSTITUTED UREA COMPOUNDS | UTS2R, ARG1, PRMT1 | FAAH 2166/4885CES2 463/4885CYP2E1 411/4885 |
| US-20120065191-A1 | PHARMACEUTICAL COMPOUNDS | FAAH, FAAH2, ASAH1 | FAAH 1/4885CES2 62/4885CYP2E1 222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.